LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 20

Search options

  1. Article ; Online: Characterisation of T cell receptor repertoires in coeliac disease.

    Lee, Lik Wee / Shafiani, Shahin / Crossley, Beryl / Emerson, Ryan O / Williamson, David / Bunin, Anna / Vargas, Justin / Han, Arnold S / Kaplan, Ian M / Green, Peter H R / Kirsch, Ilan / Bhagat, Govind

    Journal of clinical pathology

    2024  Volume 77, Issue 2, Page(s) 116–124

    Abstract: Aims: Characterise T-cell receptor gene (TR) repertoires of small intestinal T cells of patients with newly diagnosed (active) coeliac disease (ACD), refractory CD type I (RCD I) and patients with CD on a gluten-free diet (GFD).: Methods: Next- ... ...

    Abstract Aims: Characterise T-cell receptor gene (TR) repertoires of small intestinal T cells of patients with newly diagnosed (active) coeliac disease (ACD), refractory CD type I (RCD I) and patients with CD on a gluten-free diet (GFD).
    Methods: Next-generation sequencing of complementarity-determining region 3 (CDR3) of rearranged T cell receptor β (TRB) and γ (TRG) genes was performed using DNA extracted from intraepithelial cell (IEC) and lamina propria cell (LPC) fractions and a small subset of peripheral blood mononuclear cell (PBMC) samples obtained from CD and non-CD (control) patients. Several parameters were assessed, including relative abundance and enrichment.
    Results: TRB and TRG repertoires of CD IEC and LPC samples demonstrated lower clonality but higher frequency of rearranged TRs compared with controls. No CD-related differences were detected in the limited number of PBMC samples. Previously published LP gliadin-specific TRB sequences were more frequently detected in LPC samples from patients with CD compared with non-CD controls. TRG repertoires of IECs from both ACD and GFD patients demonstrated increased abundance of certain CDR3 amino acid (AA) motifs compared with controls, which were encoded by multiple nucleotide variants, including one motif that was enriched in duodenal IECs versus the PBMCs of CD patients.
    Conclusions: Small intestinal TRB and TRG repertoires of patients with CD are more diverse than individuals without CD, likely due to mucosal recruitment and accumulation of T cells because of protracted inflammation. Enrichment of the unique TRG CDR3 AA sequence in the mucosa of patients with CD may suggest disease-associated changes in the TCRγδ IE lymphocyte (IEL) landscape.
    MeSH term(s) Humans ; Celiac Disease/genetics ; Leukocytes, Mononuclear/metabolism ; T-Lymphocytes/metabolism ; Intestine, Small ; Receptors, Antigen, T-Cell/metabolism ; Intestinal Mucosa
    Chemical Substances Receptors, Antigen, T-Cell
    Language English
    Publishing date 2024-01-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 80261-x
    ISSN 1472-4146 ; 0021-9746
    ISSN (online) 1472-4146
    ISSN 0021-9746
    DOI 10.1136/jcp-2022-208541
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia.

    Fries, Carol / Lee, Lik Wee / Devidas, Meenakshi / Dai, Yunfeng / Rabin, Karen R / Gupta, Sumit / Loh, Mignon L / Kirsch, Ilan R / Wood, Brent / Rau, Rachel E

    Haematologica

    2023  Volume 108, Issue 3, Page(s) 900–904

    MeSH term(s) Child ; Humans ; Prognosis ; Immunoglobulins ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Genes, Immunoglobulin
    Chemical Substances Immunoglobulins
    Language English
    Publishing date 2023-03-01
    Publishing country Italy
    Document type Research Support, N.I.H., Extramural ; Letter
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.281146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.

    Hussaini, Mohammad O / Srivastava, Jaya / Lee, Lik Wee / Nishihori, Taiga / Shah, Bijal D / Alsina, Melissa / Pinilla-Ibarz, Javier / Shain, Kenneth H

    Archives of pathology & laboratory medicine

    2021  Volume 146, Issue 4, Page(s) 485–493

    Abstract: Context.—: Measurable (minimal) residual disease (MRD) is an independent prognostic factor for survival outcomes in patients with lymphoid and plasma cell malignancies and has been incorporated into consensus criteria regarding treatment response, ... ...

    Abstract Context.—: Measurable (minimal) residual disease (MRD) is an independent prognostic factor for survival outcomes in patients with lymphoid and plasma cell malignancies and has been incorporated into consensus criteria regarding treatment response, strategy, and clinical trial endpoints. clonoSEQ (a next-generation sequencing [NGS]-MRD assay) uses multiplex polymerase chain reaction and NGS to identify clonotypic rearrangements at the immunoglobulin (Ig) H, IgK, IgL, T-cell receptor (TCR)-β, and TCR-γ loci, as well as translocated B-cell lymphoma 1/IgH and 2/IgH sequences for MRD assessment. Additionally, it can be used to confirm diagnoses of cutaneous T-cell lymphoma (CTCL).
    Objective.—: To review the technical aspects of our experience using the clonoSEQ Assay in routine clinical practice.
    Design.—: In this single-center experience, 390 patients with lymphoid and plasma cell malignancies were assessed with the NGS-MRD Assay at a central laboratory.
    Results.—: Median time from arrival of the shipment to initiation of the assay (defined as captured in Adaptive's secure tracking system) was 2.1 hours. Overall, 317 patients had 1 or more samples submitted for sequence identification. Of these, 290 (91.5%) had trackable sequences identified. The median calibration rate of samples by malignancy (where n ≥ 10 samples, excluding CTCL samples) was 88.1%, across a variety of fresh and archived sample sources (177 of 201 samples). TCR-β and/or TCR-γ clonotypes were identified in 40 of 95 samples (42.1%) from 66 patients with suspected CTCL.
    Conclusions.—: This NGS-MRD Assay is a valuable and sensitive tool for monitoring MRD in patients with plasma cell and lymphoid malignancies and assisting in the diagnosis of CTCL.
    MeSH term(s) Gene Rearrangement ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/genetics ; Neoplasms, Plasma Cell ; Receptors, Antigen, T-Cell/genetics
    Chemical Substances Receptors, Antigen, T-Cell
    Language English
    Publishing date 2021-08-03
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 194119-7
    ISSN 1543-2165 ; 0363-0153 ; 0096-8528 ; 0003-9985
    ISSN (online) 1543-2165
    ISSN 0363-0153 ; 0096-8528 ; 0003-9985
    DOI 10.5858/arpa.2020-0457-OA
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression.

    Manjappa, Shivaprasad / Phi, Huy Q / Lee, Lik Wee / Onstad, Lynn / Gill, Darcy B / Connelly-Smith, Laura / Krakow, Elizabeth F / Flowers, Mary E / Carpenter, Paul A / Hill, Joshua A / Lee, Stephanie J

    Transplantation and cellular therapy

    2022  Volume 28, Issue 11, Page(s) 784.e1–784.e9

    Abstract: Chronic graft-versus-host disease (cGVHD) and its management with immunosuppressive therapies increase the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as well as progression to severe Coronavirus 19 disease ( ... ...

    Abstract Chronic graft-versus-host disease (cGVHD) and its management with immunosuppressive therapies increase the susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as well as progression to severe Coronavirus 19 disease (COVID-19). Vaccination against COVID-19 is strongly recommended, but efficacy data are limited in this patient population. In this study, responses to COVID-19 vaccination were measured at 3 time points-after the initial vaccine series, before the third dose, and after the third dose-in adults with cGVHD receiving immunosuppressive therapy. Humoral response was measured by quantitative anti-spike antibody and neutralizing antibody levels. Anti-nucleocapsid antibody levels were measured to detect natural infection. T cell response was evaluated by a novel immunosequencing technique combined with immune repertoire profiling from cryopreserved peripheral blood mononuclear cell samples. Present or absent T cell responses were determined by the relative proportion of unique SARS-CoV-2-associated T cell receptor sequences ("breadth") plus clonal expansion of the response ("depth") compared with those in a reference population. Based on both neutralizing antibody and T cell responses, patients were categorized as vaccine responders (both detected), nonresponders (neither detected), or mixed (one but not both detected). Thirty-two patients were enrolled for the initial series, including 17 (53%) positive responders, 7 (22%) mixed responders, and 8 (25%) nonresponders. All but one patient categorized as mixed responders had humoral responses while lacking T cell responses. No statistical differences were observed in patient characteristics among the 3 groups of patients categorized by immune response, although sample sizes were limited. Significant positive correlations were observed between the robustness of cellular and humoral responses after the initial series. Among the 20 patients with paired samples (pre- and post-third dose), a third vaccination resulted in increased neutralizing antibody titers. cGVHD worsened in 10 patients (26%; 6 after the initial series and 4 after the third dose), necessitating escalation of immunosuppressive doses in 5 patients, although 4 had been tapering immunosuppression and 5 had already worsening cGVHD at the time of vaccination, and a clear association between COVID-19 vaccination and cGVHD could not be drawn. Among the patients with cGVHD on immunosuppressive therapy, 72% demonstrated a neutralizing antibody response after a 2-dose primary COVID-19 vaccination, two-thirds of whom also developed a T cell response; 25% had neither a humoral nor a T cell response. A third dose further amplified the antibody response.
    MeSH term(s) Adult ; Humans ; COVID-19 Vaccines ; SARS-CoV-2 ; COVID-19 ; Graft vs Host Disease ; Antibodies, Viral ; Leukocytes, Mononuclear ; Vaccination/methods ; Immunity, Cellular ; Antibodies, Neutralizing ; Immunosuppression Therapy ; Immunologic Deficiency Syndromes
    Chemical Substances COVID-19 Vaccines ; Antibodies, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2022-09-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 3062231-1
    ISSN 2666-6367
    ISSN (online) 2666-6367
    DOI 10.1016/j.jtct.2022.08.026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).

    Hill, Joshua A / Martens, Michael J / Young, Jo-Anne H / Bhavsar, Kavita / Kou, Jianqun / Chen, Min / Lee, Lik Wee / Baluch, Aliyah / Dhodapkar, Madhav V / Nakamura, Ryotaro / Peyton, Kristin / Howard, Dianna S / Ibrahim, Uroosa / Shahid, Zainab / Armistead, Paul / Westervelt, Peter / McCarty, John / McGuirk, Joseph / Hamadani, Mehdi /
    DeWolf, Susan / Hosszu, Kinga / Sharon, Elad / Spahn, Ashley / Toor, Amir A / Waldvogel, Stephanie / Greenberger, Lee M / Auletta, Jeffery J / Horowitz, Mary M / Riches, Marcie L / Perales, Miguel-Angel

    medRxiv : the preprint server for health sciences

    2024  

    Abstract: Background: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood.: Objective: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after ...

    Abstract Background: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood.
    Objective: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy.
    Design: Multicenter prospective observational study.
    Setting: 34 centers in the United States.
    Participants: 466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022.
    Interventions: SARS-CoV-2 vaccination as part of routine care.
    Measurements: We obtained blood prior to and after vaccinations at up to five time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2-specific T cell receptors (TCRs), in a subgroup.
    Results: Anti-S IgG and neutralizing antibody responses increased with vaccination in HCT recipients irrespective of vaccine initiation timing but were unchanged in CAR-T cell recipients initiating vaccines within 4 months. Anti-S IgG
    Limitations: The majority of participants were adults and received mRNA vaccines.
    Conclusions: These data support starting mRNA SARS-CoV-2 vaccination three to four months after allogeneic HCT, autologous HCT, and CAR-T cell therapy.
    Funding: National Marrow Donor Program, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Novartis, LabCorp, American Society for Transplantation and Cellular Therapy, Adaptive Biotechnologies, and the National Institutes of Health.
    Language English
    Publishing date 2024-01-25
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.01.24.24301058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID.

    Grady, Connor B / Bhattacharjee, Bornali / Silva, Julio / Jaycox, Jillian / Lee, Lik Wee / Monteiro, Valter Silva / Sawano, Mitsuaki / Massey, Daisy / Caraballo, César / Gehlhausen, Jeff R / Tabachnikova, Alexandra / Mao, Tianyang / Lucas, Carolina / Peña-Hernandez, Mario A / Xu, Lan / Tzeng, Tiffany J / Takahashi, Takehiro / Herrin, Jeph / Güthe, Diana Berrent /
    Akrami, Athena / Assaf, Gina / Davis, Hannah / Harris, Karen / McCorkell, Lisa / Schulz, Wade L / Grffin, Daniel / Wei, Hannah / Ring, Aaron M / Guan, Leying / Cruz, Charles Dela / Iwasaki, Akiko / Krumholz, Harlan M

    medRxiv : the preprint server for health sciences

    2024  

    Abstract: Background: Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in ... ...

    Abstract Background: Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses may alleviate or worsen disease pathology.
    Methods: In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination.
    Results: Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health, 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after vaccination. No changes in reactivities were observed against herpes viruses and self-antigens. Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the two top features associated with non-improvement were high IFN-β and CNTF, among soluble analytes.
    Conclusions: Our study showed that in this small sample, vaccination improved the health or resulted in no change to the health of most participants, though few experienced worsening. Vaccination was associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most individuals with Long COVID. Symptom improvement was observed in those with baseline elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of improvement.
    Language English
    Publishing date 2024-01-12
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.01.11.24300929
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.

    Hill, Joshua A / Martens, Michael J / Young, Jo-Anne H / Bhavsar, Kavita / Kou, Jianqun / Chen, Min / Lee, Lik Wee / Baluch, Aliyah / Dhodapkar, Madhav V / Nakamura, Ryotaro / Peyton, Kristin / Shahid, Zainab / Armistead, Paul / Westervelt, Peter / McCarty, John / McGuirk, Joseph / Hamadani, Mehdi / DeWolf, Susan / Hosszu, Kinga /
    Sharon, Elad / Spahn, Ashley / Toor, Amir A / Waldvogel, Stephanie / Greenberger, Lee M / Auletta, Jeffery J / Horowitz, Mary M / Riches, Marcie L / Perales, Miguel-Angel

    EClinicalMedicine

    2023  Volume 59, Page(s) 101983

    Abstract: Background: The optimal timing for SARS-CoV-2 vaccines within the first year after allogeneic hematopoietic cell transplant (HCT) is poorly understood.: Methods: We conducted a prospective, multicentre, observational study of allogeneic HCT ... ...

    Abstract Background: The optimal timing for SARS-CoV-2 vaccines within the first year after allogeneic hematopoietic cell transplant (HCT) is poorly understood.
    Methods: We conducted a prospective, multicentre, observational study of allogeneic HCT recipients who initiated SARS-CoV-2 vaccinations within 12 months of HCT. Participants were enrolled at 22 academic cancer centers across the United States. Participants of any age who were planning to receive a first post-HCT SARS-CoV-2 vaccine within 12 months of HCT were eligible. We obtained blood prior to and after each vaccine dose for up to four vaccine doses, with an end-of-study sample seven to nine months after enrollment. We tested for SARS-CoV-2 spike protein (anti-S) IgG; nucleocapsid protein (anti-N) IgG; neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains; and SARS-CoV-2-specific T-cell receptors (TCRs). The primary outcome was a comparison of anti-S IgG titers at the post-V2 time point in participants initiating vaccinations <4 months versus 4-12 months after HCT using a propensity-adjusted analysis. We also evaluated factors associated with high-level anti-S IgG titers (≥2403 U/mL) in logistic regression models.
    Findings: Between April 22, 2021 and November 17, 2021, 175 allogeneic HCT recipients were enrolled in the study, of whom all but one received mRNA SARS-CoV-2 vaccines. SARS-CoV-2 anti-S IgG titers, neutralizing antibody titers, and TCR breadth and depth did not significantly differ at all tested time points following the second vaccination among those initiating vaccinations <4 months versus 4-12 months after HCT. Anti-S IgG ≥2403 U/mL correlated with neutralizing antibody levels similar to those observed in a prior study of non-immunocompromised individuals, and 57% of participants achieved anti-S IgG ≥2403 U/mL at the end-of-study time point. In models adjusted for SARS-CoV-2 infection pre-enrollment, SARS-CoV-2 vaccination pre-HCT, CD19+ B-cell count, CD4+ T-cell count, and age (as applicable to the model), vaccine initiation timing was not associated with high-level anti-S IgG titers at the post-V2, post-V3, or end-of-study time points. Notably, prior graft-versus-host-disease (GVHD) or use of immunosuppressive medications were not associated with high-level anti-S IgG titers. Grade ≥3 vaccine-associated adverse events were infrequent.
    Interpretation: These data support starting mRNA SARS-CoV-2 vaccination three months after HCT, irrespective of concurrent GVHD or use of immunosuppressive medications. This is one of the largest prospective analyses of vaccination for any pathogen within the first year after allogeneic HCT and supports current guidelines for SARS-CoV-2 vaccination starting three months post-HCT. Additionally, there are few studies of mRNA vaccine formulations for other pathogens in HCT recipients, and these data provide encouraging proof-of-concept for the utility of early vaccination targeting additional pathogens with mRNA vaccine platforms.
    Funding: National Marrow Donor Program, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Novartis, LabCorp, American Society for Transplantation and Cellular Therapy, Adaptive Biotechnologies, and the National Institutes of Health.
    Language English
    Publishing date 2023-04-27
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.101983
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Heat conduction in a two-dimensional harmonic crystal with disorder.

    Lee, Lik Wee / Dhar, Abhishek

    Physical review letters

    2005  Volume 95, Issue 9, Page(s) 94302

    Abstract: We study the problem of heat conduction in a mass-disordered two-dimensional harmonic crystal. Using two different stochastic heat baths, we perform simulations to determine the system size (L) dependence of the heat current (J). For white noise heat ... ...

    Abstract We study the problem of heat conduction in a mass-disordered two-dimensional harmonic crystal. Using two different stochastic heat baths, we perform simulations to determine the system size (L) dependence of the heat current (J). For white noise heat baths we find that J approximately 1/L(alpha) with alpha approximately equal to 0.59, while correlated noise heat baths give alpha approximately equal to 0.51. A special case with correlated disorder is studied analytically and gives alpha=3/2, which agrees also with results from exact numerics.
    Language English
    Publishing date 2005-08-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208853-8
    ISSN 1079-7114 ; 0031-9007
    ISSN (online) 1079-7114
    ISSN 0031-9007
    DOI 10.1103/PhysRevLett.95.094302
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID

    Grady, Connor B / Bhattacharjee, Bornali / Silva, Julio / Jaycox, Jillian / Lee, Lik Wee / Monteiro, Valter Silva / Sawano, Mitsuaki / Massey, Daisy / Caraballo, César / Gehlhausen, Jeff R. / Tabachnikova, Alexandra / Mao, Tianyang / Lucas, Carolina / Peña-Hernandez, Mario A. / Xu, Lan / Tzeng, Tiffany J. / Takahashi, Takehiro / Herrin, Jeph / Güthe, Diana Berrent /
    Akrami, Athena / Assaf, Gina / Davis, Hannah / Harris, Karen / McCorkell, Lisa / Schulz, Wade L / Grffin, Daniel / Wei, Hannah / Ring, Aaron M / Guan, Leying / Cruz, Charles Dela / Iwasaki, Akiko / Krumholz, Harlan M

    medRxiv

    Abstract: Background: Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in ... ...

    Abstract Background: Long COVID contributes to the global burden of disease. Proposed root cause hypotheses include the persistence of SARS-CoV-2 viral reservoir, autoimmunity, and reactivation of latent herpesviruses. Patients have reported various changes in Long COVID symptoms after COVID-19 vaccinations, leaving uncertainty about whether vaccine-induced immune responses may alleviate or worsen disease pathology. Methods: In this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and then at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination. Results: Self-report at 12 weeks post-vaccination indicated 10 out of 16 participants had improved health, 3 had no change, 1 had worse health, and 2 reported marginal changes. Significant elevation in SARS-CoV-2-specific TCRs and Spike protein-specific IgG were observed 6 and 12 weeks after vaccination. No changes in reactivities were observed against herpes viruses and self-antigens. Within this dataset, higher baseline sIL-6R was associated with symptom improvement, and the two top features associated with non-improvement were high IFN-β and CNTF, among soluble analytes. Conclusions: Our study showed that in this small sample, vaccination improved the health or resulted in no change to the health of most participants, though few experienced worsening. Vaccination was associated with increased SARS-CoV-2 Spike protein-specific IgG and T cell expansion in most individuals with Long COVID. Symptom improvement was observed in those with baseline elevated sIL-6R, while elevated interferon and neuropeptide levels were associated with a lack of improvement.
    Keywords covid19
    Language English
    Publishing date 2024-01-12
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2024.01.11.24300929
    Database COVID19

    Kategorien

  10. Article ; Online: SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)

    Hill, Joshua A. / Martens, Michael J. / Young, Jo-Anne H. / Bhavsar, Kavita / Kou, Jianqun / Chen, Min / Lee, Lik Wee / Baluch, Aliyah / Dhodapkar, Madhav V. / Nakamura, Ryotaro / Peyton, Kristin / Howard, Dianna S. / Ibrahim, Uroosa / Shahid, Zainab / Armistead, Paul / Westervelt, Peter / McCarty, John / McGuirk, Joseph / Hamadani, Mehdi /
    DeWolf, Susan / Hosszu, Kinga / Sharon, Elad / Spahn, Ashley / Toor, Amir A. / Waldvogel, Stephanie / Greenberger, Lee M. / Auletta, Jeffery J. / Horowitz, Mary M. / Riches, Marcie L. / Perales, Miguel-Angel

    medRxiv

    Abstract: Background The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood. Objective To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after ... ...

    Abstract Background The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood. Objective To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy. Design Multicenter prospective observational study. Setting 34 centers in the United States. Participants 466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022. Interventions SARS-CoV-2 vaccination as part of routine care. Measurements We obtained blood prior to and after vaccinations at up to five time points and tested for SARS-CoV-2 spike (anti-S) IgG in all participants and neutralizing antibodies for Wuhan D614G, Delta B.1.617.2, and Omicron B.1.1.529 strains, as well as SARS-CoV-2-specific T cell receptors (TCRs), in a subgroup. Results Anti-S IgG and neutralizing antibody responses increased with vaccination in HCT recipients irrespective of vaccine initiation timing but were unchanged in CAR-T cell therapy recipients initiating vaccines within 4 months. Anti-S IgG ≥2,500 U/mL was correlated with high neutralizing antibody titers and attained by the last time point in 70%, 69%, and 34% of allogeneic HCT, autologous HCT, and CAR-T cell therapy recipients, respectively. SARS-CoV-2-specific T cell responses were attained in 57%, 83%, and 58%, respectively. Humoral and cellular responses did not significantly differ among participants initiating vaccinations <4 months vs 4-12 months after cellular therapy. Pre-cellular therapy SARS-CoV-2 infection or vaccination were key predictors of post-cellular therapy anti-S IgG levels. Limitations The majority of participants were adults and received mRNA vaccines. Conclusions These data support starting mRNA SARS-CoV-2 vaccination three to four months after allogeneic HCT, autologous HCT, and CAR-T cell therapy. Funding National Marrow Donor Program, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Novartis, LabCorp, American Society for Transplantation and Cellular Therapy, Adaptive Biotechnologies, and the National Institutes of Health
    Keywords covid19
    Language English
    Publishing date 2024-01-25
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2024.01.24.24301058
    Database COVID19

    Kategorien

To top